Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Novartis
Kivu Bioscience Inc.
Travera Inc
Bayer
Actuate Therapeutics Inc.
FindCure Biosciences (ZhongShan) Co., Ltd.
Hoffmann-La Roche
ViroMissile, Inc.
Angiex, Inc.
MacroGenics
Avacta Life Sciences Ltd
Adela, Inc
Eli Lilly and Company
Var2 Pharmaceuticals
Tanabe Pharma America, Inc.
Stella Pharma Corporation
Bayer
Actym Therapeutics, Inc.
AVM Biotechnology Inc
Pfizer
Eli Lilly and Company
Sensei Biotherapeutics, Inc.
Baxter Healthcare Corporation
OncoC4, Inc.
Tempus AI
Elevation Oncology
Labcorp Corporation of America Holdings, Inc
Intensity Therapeutics, Inc.
BostonGene
Cybrexa Therapeutics
Deciphera Pharmaceuticals, LLC
Cyteir Therapeutics, Inc.
Taproot Health
Shanghai PerHum Therapeutics Co., Ltd.
Mundipharma Research Limited
Prelude Therapeutics
Gene Surgery LLC
DNAtrix, Inc.
Cellestia Biotech AG
Corvus Pharmaceuticals, Inc.
Prelude Therapeutics
Pfizer
pharmaand GmbH
Hoffmann-La Roche
Shanghai Yunying Medical Technology
Kineta Inc.
Shanghai Yunying Medical Technology
Shanghai Yunying Medical Technology
Pfizer